Is COPD a Risk Factor for Cardiovascular Disease?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02162095|
Recruitment Status : Completed
First Posted : June 12, 2014
Last Update Posted : June 3, 2015
|Condition or disease|
|Chronic Obstructive Pulmonary Disease|
Patients with chronic obstructive pulmonary disease (COPD) suffer from significant cardiovascular morbidity and mortality. Coronary artery disease has often been linked causally to COPD, but the exact pathophysiological mechanisms underpinning this association remain speculative. A retrospective case-control study matching COPD patients and controls one to one for smoking history and conventional cardiovascular risk factors will be performed to study the association between COPD and cardiovascular outcomes. Filling in this knowledge gap may contribute to the understanding of the interplay between COPD and cardiovascular disease.
The objective of this retrospective case-control study is to determine whether COPD might be a risk factor for coronary atherosclerosis, impaired left ventricular ejection fraction, and major adverse cardiovascular events independent of conventional cardiovascular risk factors.
|Study Type :||Observational|
|Actual Enrollment :||162 participants|
|Observational Model:||Case Control|
|Official Title:||Is Chronic Obstructive Pulmonary Disease a Risk Factor for Cardiovascular Disease?|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Chronic obstructive pulmonary disease
Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
- Coronary calcium score in cardiac computed tomography [ Time Frame: Up to one month ]Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.
- Left ventricular ejection fraction in single-photon emission computed tomography [ Time Frame: Up to one month ]Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.
- Major adverse cardiovascular events [ Time Frame: Up to three months ]Follow-up via telephone interview for major adverse cardiovascular events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02162095
|University Hospital Zurich, Pulmonary Division|
|Zurich, Switzerland, 8091|
|Principal Investigator:||Malcolm Kohler, MD, Prof||University of Zurich|